Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

11289	Companies
250843	Keywords
179648	Articles
136680	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 2 years 4 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 2 years 4 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 2 years 4 months ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 2 years 4 months ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 2 years 4 months ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 2 years 4 months ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 2 years 5 months ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 5 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 5 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 2 years 6 months ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity

Accesswire

Published on 11/06/2026 at 01:20, 1 hour 21 minutes ago

Presentation to Munich Mining Conference
Published on 11/06/2026 at 00:53, 1 hour 48 minutes ago

Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 1 hour 56 minutes ago

Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/05/2026 at 23:20, 3 hours 21 minutes ago

Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Published on 11/05/2026 at 22:05, 4 hours 36 minutes ago

Innodata Reports Record Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/06/2026 at 00:05, 2 hours 36 minutes ago

RBI: Announcement of the result of the voluntary public tender offer for all Addiko shares following expiration of the grace period
Published on 11/05/2026 at 22:05, 4 hours 36 minutes ago

Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
Published on 11/05/2026 at 20:38, 6 hours 2 minutes ago

freenet uses funds from Ceconomy sale for waipu.tv acquisition and share buyback
Published on 11/05/2026 at 20:37, 6 hours 4 minutes ago

EQS-Adhoc: freenet AG decides on share buyback programme for up to EUR 75 million
Published on 11/05/2026 at 19:45, 6 hours 55 minutes ago

Stabilus SE fulfills forecast for fiscal 2026 and adjusts 2030 medium-term targets

Les Echos

Published on 11/05/2026 at 18:21, 8 hours 19 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:50, 8 hours 51 minutes ago

NRJ GROUP - Financial information Q3 2026
Published on 11/05/2026 at 17:45, 8 hours 56 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 9 hours 11 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
Published on 11/05/2026 at 10:16, 16 hours 24 minutes ago

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

View all LES ECHOS COMFI WIRE